| dc.contributor.author | Wurtman, Richard J., 1936- | en_US |
| dc.coverage.temporal | Fall 2003 | en_US |
| dc.date.issued | 2003-12 | |
| dc.identifier | 9.15-Fall2003 | |
| dc.identifier | local: 9.15 | |
| dc.identifier | local: 9.150 | |
| dc.identifier | local: IMSCP-MD5-1c8c5dbf83e4efdf56c7aa0c9344e1a0 | |
| dc.identifier.uri | http://hdl.handle.net/1721.1/45133 | |
| dc.description.abstract | Considers the process of neurotransmission, especially chemicals used in the brain and elsewhere to carry signals from nerve terminals to the structures they innervate. Focuses on monoamine transmitters (acetylcholine; serotonin; dopamine and norepinephrine); also examines amino acid and peptide transmitters and neuromodulators like adenosine. Macromolecules that mediate neurotransmitter synthesis, release, inactivation, and receptor-mediated actions are discussed, as well as factors that regulate their activity and the second-messenger systems they control. Alternate years. | en_US |
| dc.language | en-US | en_US |
| dc.relation | | en_US |
| dc.relation | | en_US |
| dc.rights.uri | Usage Restrictions: This site (c) Massachusetts Institute of Technology 2003. Content within individual courses is (c) by the individual authors unless otherwise noted. The Massachusetts Institute of Technology is providing this Work (as defined below) under the terms of this Creative Commons public license ("CCPL" or "license"). The Work is protected by copyright and/or other applicable law. Any use of the work other than as authorized under this license is prohibited. By exercising any of the rights to the Work provided here, You (as defined below) accept and agree to be bound by the terms of this license. The Licensor, the Massachusetts Institute of Technology, grants You the rights contained here in consideration of Your acceptance of such terms and conditions. | en_US |
| dc.subject | neurotransmitter | en_US |
| dc.subject | antidepressant | en_US |
| dc.subject | brain lipid | en_US |
| dc.subject | blood brain barrier | en_US |
| dc.subject | dopamine | en_US |
| dc.subject | parkinson's disease | en_US |
| dc.subject | seratonin | en_US |
| dc.subject | depression | en_US |
| dc.subject | glutamate | en_US |
| dc.subject | aspartate | en_US |
| dc.subject | NDMA | en_US |
| dc.subject | drug | en_US |
| dc.subject | drug discovery | en_US |
| dc.subject | pharmaceutical | en_US |
| dc.subject | signaling pathway | en_US |
| dc.subject | receptor | en_US |
| dc.subject | spinal cord | en_US |
| dc.subject | marijuana | en_US |
| dc.subject | adensosine | en_US |
| dc.subject | histamine | en_US |
| dc.subject | 9.15 | en_US |
| dc.subject | 9.150 | en_US |
| dc.title | 9.15 / 9.150 Biochemistry and Pharmacology of Synaptic Transmission, Fall 2003 | en_US |
| dc.title.alternative | Biochemistry and Pharmacology of Synaptic Transmission | en_US |
